Incyte Corporation

$62.03
(as of May 1, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Incyte Corporation

Stock Price
$62.03
Ticker Symbol
INCY
Exchange
NASDAQ

Industry Information for Incyte Corporation

Sector
Healthcare
Industry
Biotechnology

Company Description for Incyte Corporation

Country
USA
Full Time Employees
2,617

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Fundamentals for Incyte Corporation

Market Capitalization
$12,126,214,144
EBITDA
$300,191,008
Dividends per Share
P/E Ratio
417.73
Forward P/E Ratio
9.78
Earnings per Share
$0.15
Earnings per Share Estimate Next Year
Profit Margin
0.48%
Shares Outstanding
193,524,000
Percent Owned by Insiders
2.08%
Percent Owned by Institutions
97.08%
52-Week High
52-Week Low

Technical Indicators for Incyte Corporation

50-Day Moving Average
200-Day Moving Average
RSI
55.31
2.27

Analyst Ratings for Incyte Corporation

Strong Buy
8
Buy
2
Hold
16
Sell
1
Strong Sell
0

News About Incyte Corporation

May 1, 2025, 8:00 AM EST
WILMINGTON, Del., May 01, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT). See more.
Apr 30, 2025, 7:19 AM EST
Incyte (NASDAQ:INCY) First Quarter 2025 Results See more.
Apr 30, 2025, 3:06 AM EST
Total Revenue: $1.05 billion, up 20% year-over-year. See more.
Apr 29, 2025, 11:04 AM EST
Incyte Corporation INCY reported first-quarter 2025 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.01. See more.